Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

@article{Chapman2011ImprovedSW,
  title={Improved survival with vemurafenib in melanoma with BRAF V600E mutation.},
  author={Paul B. Chapman and Axel Hauschild and Caroline Robert and John B.A.G. Haanen and Paolo Antonio Ascierto and James M. G. Larkin and Reinhard Dummer and Claus Garbe and Alessandro A. E. Testori and Michele Maio and David Hogg and Paul C. Lorigan and C{\'e}leste Lebb{\'e} and Thomas Jouary and Dirk Schadendorf and Antoni Ribas and Steven J. O’Day and Jeffrey A. Sosman and John M. Kirkwood and Alexander M. M. Eggermont and Brigitte Dr{\'e}no and Keith B. Nolop and Jiang Li and Betty Nelson and Jeannie Whit-shan Hou and Richard J Lee and Keith T. Flaherty and Grant A. McArthur},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 26},
  pages={
          2507-16
        }
}
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. [...] Key Method Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival.Expand
Vemurafenib: in unresectable or metastatic melanoma.
  • G. Keating
  • Medicine
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 2012
TLDR
Oral vemurafenib was generally well tolerated in patients with metastatic melanoma, with cutaneous adverse events among the most commonly occurring adverse events.
Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
TLDR
C crossover from dacarbazine to vemurafenib was recommended after review of the interim analysis by an independent data and safety monitoring board, and vemurafenIB was associated with a relative reduction in the risk of death and disease progression as compared with dACarbazine.
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
  • S. Kopetz, J. Desai, +14 authors L. Saltz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
TLDR
Single-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC, and combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
TLDR
Vemurafenib safety in this diverse population of patients with BRAF(V600) mutated metastatic melanoma, who are more representative of routine clinical practice, was consistent with the safety profile shown in the pivotal trials of this drug.
Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial
TLDR
This study confirms the considerable clinical benefit of vemurafenib for patients with brain metastasis, with manageable toxicity, in phase 2 and 3 trials of BRAF V600E metastatic melanoma.
Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.
TLDR
The combination of vemurafenib plus fotemustine has clinical activity and an acceptable safety profile in BRAF-refractory patients and is associated with improved overall survival.
Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
TLDR
The results suggest that continuing vemurafenib treatment beyond progression may be beneficial in advanced melanoma patients, who prior to progression responded to vemurAFenib.
The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial
TLDR
The overall safety profile and response rate of vemurafenib were comparable to those reported in previous studies of this drug, and confirmed the value of well-established prognostic features for overall survival, such as initial LDH (lactate dehydrogenase) level and AJCC staging.
Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
TLDR
Overall, vemurafenib showed a favorable benefit-risk profile among Chinese patients and Pharmacokinetics, safety, and efficacy were generally consistent with those reported in Caucasian patients.
Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial.
TLDR
Combination therapy was well tolerated with a reduced incidence of cutaneous squamous-cell carcinoma/keratoacanthoma and may be a starting point for novel combination strategies with immunotherapies and other targeted therapies.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
  • A. Ribas, K. Kim, +17 authors J. Sosman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
BRIM-2 met its primary endpoint based on BORR, confirming that V is an active agent in pts with BRAF mutation-positive melanoma who have completed prior first-line therapy, and was generally reversible with dose modification or interruption.
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
  • M. Middleton, J. Grob, +16 authors N. Thatcher
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
Temozolomide demonstrates efficacy equal to that of DTIC and is an oral alternative for patients with advanced metastatic melanoma.
Inhibition of mutated, activated BRAF in metastatic melanoma.
TLDR
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
TLDR
There was no difference in survival time and only a small, statistically nonsignificant increase in tumor response for stage IV melanoma patients treated with the Dartmouth regimen compared with dacarbazine.
Improved survival with ipilimumab in patients with metastatic melanoma.
TLDR
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
TLDR
The addition of oblimersen to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival in patients without an elevated baseline serum LDH.
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
  • M. Avril, S. Aamdal, +17 authors Y. Menu
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
ORR was higher in the fotemustine arm compared to the DTIC arm in first-line treatment of disseminated melanoma, and a trend in favor of fotamustine in terms of overall survival and time to BM was evidenced.
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
  • G. Long, A. Menzies, +7 authors R. Kefford
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
The presence of mutant BRAF had no impact on the disease-free interval from diagnosis of first-ever melanoma to first distant metastasis; however, it may have impacted survival thereafter.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
TLDR
The structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity, and a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily are described, demonstrating that BRAF-mutant melanomas are highly dependent on B- RAF kinases activity.
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.
  • J. Wolchok, L. Thomas, +7 authors C. Robert
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
IPI (10mg/kg) + DTIC significantly improved OS in 1st line metastatic melanoma vs DTIC alone; durable survival and objective responses were noted in some pts after follow-up for up to 4yrs.
...
1
2
3
4
...